Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1999, for OXIS International, Inc. (Note: The filing header identifies the registrant as OXIS International, Inc., despite the request metadata referencing GT Biopharma, Inc.). The company operates in two segments: Health Therapeutic Products and Development. The company is currently in a development phase, relying on product sales and royalties while incurring significant research and development costs.
Key Financial Metrics
- Revenue: Total revenues were $1,456,000 for the quarter ended March 31, 1999, compared to $1,347,000 in the prior year period.
- Profitability: The company reported a net loss of $1,191,000 ($0.15 per share), an improvement from the $1,840,000 net loss ($0.32 per share) in the first quarter of 1998.
- Cash Flow: Net cash used for operating activities was $1,522,000. Net cash provided by investing activities was $1,909,000, primarily due to proceeds from the sale of land and buildings. Net cash used for financing activities was $1,502,000, driven by debt repayments.
- Liquidity: Cash and cash equivalents decreased from $2,575,000 at December 31, 1998, to $1,483,000 at March 31, 1999. Working capital decreased by $415,000 to $2,615,000.
- Debt: Total debt obligations include $724,000 in notes payable, $48,000 in current portion of long-term debt, and $174,000 in long-term debt due after one year.
- Margins: Cost of sales as a percentage of product sales decreased to 72% in Q1 1999 from 97% in Q1 1998. Excluding amortization of purchase adjustments, the cost of sales was approximately 57% of product sales.
Material Changes Versus Prior Period
- Revenue Mix: Sales of diagnostic and research assays increased significantly by $432,000 to $848,000, driven by higher distributor volumes. Conversely, revenue from instrument sales and development declined by $323,000 to $487,000 due to reduced orders from original equipment manufacturing customers.
- Expense Reductions: Research and development expenses decreased by $161,000 to $770,000, largely due to the closure of the French research laboratory and reduced outside development contracts. Selling, general, and administrative expenses decreased by $123,000 to $858,000 following the consolidation of sales functions.
- Asset Liquidation: The company sold land and buildings, generating $1,959,000 in proceeds and a gain of $16,000, which significantly impacted investing cash flows and reduced property and equipment assets.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue reporting losses in 1999 as expenses are projected to exceed revenues. The company anticipates needing new revenue sources or additional capital to continue operations according to current plans.
- Liquidity Risk: Failure to generate new revenue or raise additional capital could force the company to severely curtail or cease operations. The company has no assurance regarding the timing or success of business alliances required to commercialize therapeutic products.
- Year 2000 Compliance: The company is addressing Year 2000 issues in its hardware and software. Estimated costs for upgrades and replacements are expected not to exceed $100,000. There is a risk that third-party vendors may fail to be compliant, potentially impacting operations.
- Operational Changes: The French research laboratory was closed in early 1999, with remaining employees expected to be terminated in the second quarter of 1999.
Investor Verification Checklist
- Verify the company's ability to secure additional capital or new revenue sources to sustain operations beyond current cash reserves of $1.48 million.
- Confirm the status of business alliances with biotechnology or pharmaceutical companies necessary to develop and market therapeutic products.
- Monitor the timeline and costs associated with Year 2000 compliance upgrades and the potential impact of vendor non-compliance.
- Assess the sustainability of the increased sales volume in diagnostic and research assays versus the decline in instrument sales.
- Review the impact of the French laboratory closure on future R&D capabilities and associated severance costs.